查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462625

到 2030 年免疫组织化学 (IHC) 市场预测：按产品、应用、最终用户和地区分類的全球分析

Immunohistochemistry (IHC) Market Forecasts to 2030 - Global Analysis By Product (Antibodies, Reagents and Other Products), Application (Diagnostic Application, Research application and Other Applications), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球免疫组织化学 (IHC) 市场规模为 25 亿美元，预计到 2030 年将达到 47.2 亿美元，预测期内复合年增长率为 9.50%。

免疫组织化学 (IHC) 是一种用于病理学和生物医学研究的强大技术，可可视觉化组织样本中特定蛋白质和抗原的存在、定位和丰度。它使用与固定组织切片中的目标蛋白结合的抗体。透过抗原修復、封闭、一抗孵育和二抗检测等一系列步骤，IHC 能够辨识特定的细胞成分和标记。

根据美国癌症协会2023年癌症统计数据，预计2023年美国将诊断出196万新发癌症病例，高于2021年的189万例。

更多地采用伴同性诊断

伴同性诊断透过帮助为每位患者选择最有效的治疗方法，在个人化医疗中发挥重要作用。免疫组织化学技术对于伴同性诊断至关重要，可以识别组织内的特定生物标记和分子标靶。随着精准医学的不断发展，对免疫组织化学技术支援的伴同性诊断的需求不断增加，特别是在肿瘤学和其他需要标靶治疗的领域。随着医疗保健提供者根据患者特定特征和分子谱优先考虑客製化治疗方法，预计这一趋势将推动免疫组织化学市场的扩张。

有限的标准化

有限的标准化是指缺乏普遍接受的样品製备、染色技术和结果解释的方案或指南。这种标准化的缺乏给研究人员和临床医生在不同的实验室和平台上获得一致和可重复的结果带来了挑战。这会导致染色强度、特异性和灵敏度的变化，影响 IHC资料的可靠性和可比性。因此，这项限制阻碍了 IHC 在临床诊断和研究应用中的普及，限制了其导致治疗决策和科学理解进步的潜力。

癌症研究与诊断

IHC 可以准确检测和定位组织样本中的特定蛋白质，从而帮助癌症诊断、预后和治疗计划。 IHC 技术的进步使研究人员和临床医生能够识别与各种癌症类型相关的生物标誌物，从而实现个人化医疗方法。该技术还促进了肿瘤微环境的研究，有助于更深入地了解癌症生物学和潜在的治疗标靶。随着对准确癌症诊断和标靶治疗的需求持续增长，IHC 市场有望进一步扩大并提供创新的解决方案，以改善患者的治疗和结果。

价格敏感度

价格敏感度威胁是指顾客对价格变动高度敏感所带来的风险。 IHC 涉及昂贵的试剂、设备和专业知识，因此定价在购买决策中起着重要作用。在价格敏感的市场中，如果价格上涨，客户可能会选择更便宜的替代品或减少使用。因此，对 IHC 产品和服务的需求可能会减少，从而影响该领域公司的收益和报酬率。为了减轻这种威胁，公司必须仔细平衡定价策略与维持产品品质和价值提案，同时也要考虑竞争格局和顾客需求。

COVID-19 的影响：

人们越来越关注了解病毒并开发有效的诊断和治疗方法，导致对检测病毒抗原和评估病毒组织损伤的 IHC 测试的需求激增。此外，关闭期间医疗服务和研究活动的中断暂时减缓了市场成长。然而，疫情也加速了 IHC 检测和自动化技术的进步，从而提高了测试过程的效率和准确性。总体而言，虽然疫情带来了挑战，但它凸显了 IHC 在疾病诊断和管理中的重要性，这可能会推动市场的长期成长。

预计设备产业在预测期内将是最大的。

由于技术进步导致更有效率和用户友好的设备的开发，设备领域经历了显着的增长。癌症和慢性病的盛行率不断上升，刺激了对 IHC 等诊断技术的需求，从而推动了相关设备市场的发展。此外，全球医疗保健支出的增加促使医疗机构投资现代设备，以提供更好的患者照护。此外，免疫组织化学技术在研究和药物开发中的日益增长的应用进一步推动了该领域设备的需求。

研究应用预计在预测期内具有最高的复合年增长率

随着更先进、更灵敏的 IHC 检测方法的产生，以满足复杂的研究需求，研究应用领域正在经历显着的成长。肿瘤学、神经科学和免疫学等领域研究范围的扩大正在推动对 IHC 技术的需求，以分析组织样本以进行生物标记识别和表征。此外，学术机构、研究机构和生物技术公司之间的合作正在推动 IHC 在各种研究计划中的采用。此外，全球生物医学研究支出的增加使得利用 IHC 探索新的应用和检验潜在的治疗标靶成为可能，进一步推动了这一领域的成长。

比最大的地区

由于癌症等慢性疾病的盛行率不断上升、对个人化医疗的需求不断增长以及诊断技术的进步，北美地区的免疫组织化学 (IHC) 领域呈现显着增长。有利的报销政策、强大的医疗基础设施以及主要市场参与者的强大影响力正在促进北美 IHC 市场的扩张。此外，由于不断努力提高诊断技术的效率和准确性，对研发活动的投资不断增加，这进一步推动了市场的成长。

复合年增长率最高的地区：

由于人口老化的增加，亚太地区正在经历显着的成长。中国和印度等国家不断增长的医疗保健支出和基础设施发展正在促进市场扩张。此外，自动化和数位病理学等技术进步正在提高免疫组织化学测试的效率和准确性，进一步推动市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次研究资料
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球免疫组织化学 (IHC) 市场：副产品

  • 抗体
    • 一抗
    • 二抗
  • 试剂
    • 冲淡
    • 蛋白水解酶
    • 封闭血清和试剂
    • 固定试剂
    • 组织学染色
    • 呈色受质
    • 有机溶剂
    • 稳定剂
    • 安装方案
    • 抗原修復液
    • 其他试剂
  • 套件
    • 动物组织 IHC套件
    • 人体组织 IHC套件
  • 装置
    • 幻灯片扫描仪
    • 自动盖拖鞋
    • 切片机
    • 视觉化装置
    • 滑动贴标机
    • 组织微阵列
    • 石蜡分配器
    • 玻片染色系统
    • 组织处理系统
    • 其他设备
  • 其他产品

第六章全球免疫组织化学 (IHC) 市场：依应用分类

  • 诊断用途
    • 癌症
    • 感染疾病
    • 自体免疫疾病
    • 肾臟疾病
    • 神经系统疾病
    • 眼科
    • 牙科疾病
    • 心血管
    • 皮肤科
    • 其他诊断应用
  • 研究用途
    • 药物开发和测试
    • 发育生物学
    • 干细胞研究
    • 法医学应用
    • 其他研究用途
  • 其他用途

第七章全球免疫组织化学 (IHC) 市场：按最终用户分类

  • 法医学研究所
  • 生物製药公司
  • 医院和诊断实验室
  • 学术研究所
  • 其他最终用户

第八章全球免疫组织化学 (IHC) 市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 10 章 公司概况

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Becton Dickinson and Company
  • Bio SB
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-LA Roche AG
  • Merck KGaA
  • PerkinElmer, Inc.
  • Takara Bio
  • Thermo Fisher Scientific Inc.
Product Code: SMRC25676

According to Stratistics MRC, the Global Immunohistochemistry (IHC) Market is accounted for $2.50 billion in 2023 and is expected to reach $4.72 billion by 2030 growing at a CAGR of 9.50% during the forecast period. Immunohistochemistry (IHC) is a powerful technique used in the field of pathology and biomedical research to visualize the presence, localization, and abundance of specific proteins or antigens within tissue samples. It involves the use of antibodies that bind to target proteins in fixed tissue sections. Through a series of steps, including antigen retrieval, blocking, primary antibody incubation, and detection with a secondary antibody, IHC enables the identification of specific cellular components or markers.

According to the American Cancer Society 2023 Cancer Statistics, it is estimated that about 1.96 million new cases of cancer would be diagnosed in the United States in 2023, as compared to 1.89 million in 2021.

Market Dynamics:

Driver:

Increasing adoption of companion diagnostics

Companion diagnostics play a crucial role in personalized medicine by aiding in the selection of the most effective treatment for individual patients. Immunohistochemistry techniques are integral to companion diagnostics, enabling the identification of specific biomarkers and molecular targets within tissues. As precision medicine continues to gain traction, demand for companion diagnostics supported by immunohistochemistry techniques is growing, particularly in oncology and other areas requiring targeted therapies. This trend is expected to drive the expansion of the immunohistochemistry market as healthcare providers prioritize tailored treatment approaches based on patients' unique characteristics and molecular profiles.

Restraint:

Limited standardization

Limited standardization refers to the absence of universally accepted protocols and guidelines for sample preparation, staining techniques, and interpretation of results. This lack of standardization poses challenges for researchers and clinicians in achieving consistent and reproducible results across different laboratories and platforms. It leads to variations in staining intensity, specificity, and sensitivity, impacting the reliability and comparability of IHC data. Consequently, this constraint hinders the widespread adoption of IHC in clinical diagnostics and research applications, limiting its potential for guiding treatment decisions and advancing scientific understanding.

Opportunity:

Cancer research and diagnostics

IHC allows for the precise detection and localization of specific proteins within tissue samples, aiding in cancer diagnosis, prognosis, and treatment planning. With advancements in IHC technologies, researchers and clinicians can identify biomarkers associated with different cancer types, enabling personalized medicine approaches. This technique also facilitates the study of tumor microenvironments, contributing to a deeper understanding of cancer biology and potential therapeutic targets. As the demand for accurate cancer diagnosis and targeted therapies continues to grow, the IHC market stands poised to expand further, offering innovative solutions for improved patient care and outcomes.

Threat:

Price sensitivity

The price sensitivity threats are the risks posed by customers being highly responsive to changes in pricing. As IHC involves costly reagents, equipment, and expertise, pricing plays a critical role in purchasing decisions. In a price-sensitive market, customers may opt for cheaper alternatives or reduce their usage if prices rise. This can lead to decreased demand for IHC products and services, impacting revenues and profitability for companies operating in this sector. To mitigate this threat, companies must carefully balance pricing strategies with maintaining product quality and value propositions while also considering the competitive landscape and customer needs.

Covid-19 Impact:

With increased focus on understanding the virus and developing effective diagnostics and therapies, there has been a surge in demand for IHC tests for detecting viral antigens and assessing tissue damage caused by the virus. Additionally, disruptions in healthcare services and research activities during lockdowns have temporarily slowed down market growth. However, the pandemic has also accelerated technological advancements in IHC assays and automation, leading to greater efficiency and accuracy in testing processes. Overall, while the pandemic has posed challenges, it has also highlighted the importance of IHC in disease diagnosis and management, potentially driving long-term growth in the market.

The equipment segment is expected to be the largest during the forecast period

The equipment segment has been experiencing significant growth due to developments in technologies, which have led to the development of more efficient and user-friendly equipment. The increasing prevalence of cancer and chronic diseases has fueled demand for diagnostic techniques like IHC, thereby driving the market for related equipment. Moreover, rising healthcare expenditures globally have enabled healthcare facilities to invest in modern equipment for better patient care. Furthermore, the expanding application of immunohistochemistry techniques in research and drug development has further boosted demand for equipment in this segment.

The research application segment is expected to have the highest CAGR during the forecast period

The research application segment has experienced notable growth due to manufacturing of more sophisticated and sensitive IHC assays, catering to the complex requirements of research studies. The expanding scope of research in areas such as oncology, neuroscience, and immunology has fueled the demand for IHC techniques to analyze tissue samples for biomarker identification and characterization. Moreover, collaborations between academic institutions, research organizations, and biotechnology companies have facilitated the adoption of IHC in diverse research projects. Additionally, the rise in funding for biomedical research globally has further propelled the growth of this segment, enabling the exploration of novel applications and the validation of potential therapeutic targets using IHC.

Region with largest share:

North American region has witnessed substantial growth in the immunohistochemistry (IHC) because of the increasing prevalence of chronic diseases such as cancer, rising demand for personalized medicine, and advancements in diagnostic technologies. Favorable reimbursement policies, robust healthcare infrastructure, and a strong presence of key market players contribute to the expansion of the IHC market in North America. Furthermore, growing investments in research and development activities further propel market growth, with continuous efforts aimed at enhancing the efficiency and accuracy of diagnostic techniques.

Region with highest CAGR:

The Asia-Pacific region has experienced significant growth in the due to a growing number of geriatric population. The rising healthcare expenditure and infrastructure development in countries like China and India have contributed to market expansion. Additionally, advancements in technology, such as automation and digital pathology, have improved efficiency and accuracy in immunohistochemistry procedures, further driving market growth.

Key players in the market

Some of the key players in Immunohistochemistry (IHC) market include Abcam PLC, Agilent Technologies, Inc., Becton Dickinson and Company, Bio SB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-LA Roche AG, Merck KGaA, PerkinElmer, Inc., Takara Bio and Thermo Fisher Scientific Inc.

Key Developments:

In March 2024, Thermo Fisher Scientific Inc. announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas' 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

In February 2024, Danaher Corporation has launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials. As part of the Danaher Beacons program, the multi-year collaboration aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients.

Products Covered:

  • Antibodies
  • Reagents
  • Kits
  • Equipment
  • Other Products

Applications Covered:

  • Diagnostic Application
  • Research application
  • Other Applications

End Users Covered:

  • Forensic Laboratories
  • Biopharma Companies
  • Hospitals & Diagnostic Laboratories
  • Academic & research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunohistochemistry (IHC) Market, By Product

  • 5.1 Introduction
  • 5.2 Antibodies
    • 5.2.1 Primary antibodies
    • 5.2.2 Secondary antibodies
  • 5.3 Reagents
    • 5.3.1 Diluents
    • 5.3.2 Proteolytic Enzymes
    • 5.3.3 Blocking Sera and Reagents
    • 5.3.4 Fixation Reagents
    • 5.3.5 Histological Stains
    • 5.3.6 Chromogenic Substrates
    • 5.3.7 Organic Solvents
    • 5.3.8 Stabilizers
    • 5.3.9 Mounting Solutions
    • 5.3.10 Antigen Retrieval Solutions
    • 5.3.11 Other Reagents
  • 5.4 Kits
    • 5.4.1 IHC Kits for Animal tissue
    • 5.4.2 IHC Kits for Human tissue
  • 5.5 Equipment
    • 5.5.1 Slide Scanners
    • 5.5.2 Automated Cover Slippers
    • 5.5.3 Microtomes
    • 5.5.4 Visualization Equipment
    • 5.5.5 Slide Labelers
    • 5.5.6 Tissue Microarrays
    • 5.5.7 Paraffin Dispensers
    • 5.5.8 Slide-staining Systems
    • 5.5.9 Tissue Processing Systems
    • 5.5.10 Other Equipment
  • 5.6 Other Products

6 Global Immunohistochemistry (IHC) Market, By Application

  • 6.1 Introduction
  • 6.2 Diagnostic Application
    • 6.2.1 Cancer
    • 6.2.2 Infectious diseases
    • 6.2.3 Autoimmune diseases
    • 6.2.4 Nephrological diseases
    • 6.2.5 Neurological diseases
    • 6.2.6 Ophthalmic
    • 6.2.7 Dental Diseases
    • 6.2.8 Cardiovascular
    • 6.2.9 Dermatological
    • 6.2.10 Other Diagnostic Applications
  • 6.3 Research application
    • 6.3.1 Drug development and Testing
    • 6.3.2 Developmental Biology
    • 6.3.3 Stem Cell Research
    • 6.3.4 Forensic applications
    • 6.3.5 Other Research Applications
  • 6.4 Other Applications

7 Global Immunohistochemistry (IHC) Market, By End User

  • 7.1 Introduction
  • 7.2 Forensic Laboratories
  • 7.3 Biopharma Companies
  • 7.4 Hospitals & Diagnostic Laboratories
  • 7.5 Academic & research Institutes
  • 7.6 Other End Users

8 Global Immunohistochemistry (IHC) Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abcam PLC
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Becton Dickinson and Company
  • 10.4 Bio SB
  • 10.5 Bio-Rad Laboratories, Inc.
  • 10.6 Bio-Techne Corporation
  • 10.7 Cell Signaling Technology, Inc.
  • 10.8 Danaher Corporation
  • 10.9 F. Hoffmann-LA Roche AG
  • 10.10 Merck KGaA
  • 10.11 PerkinElmer, Inc.
  • 10.12 Takara Bio
  • 10.13 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Immunohistochemistry (IHC) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immunohistochemistry (IHC) Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Immunohistochemistry (IHC) Market Outlook, By Antibodies (2021-2030) ($MN)
  • Table 4 Global Immunohistochemistry (IHC) Market Outlook, By Primary antibodies (2021-2030) ($MN)
  • Table 5 Global Immunohistochemistry (IHC) Market Outlook, By Secondary antibodies (2021-2030) ($MN)
  • Table 6 Global Immunohistochemistry (IHC) Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 7 Global Immunohistochemistry (IHC) Market Outlook, By Diluents (2021-2030) ($MN)
  • Table 8 Global Immunohistochemistry (IHC) Market Outlook, By Proteolytic Enzymes (2021-2030) ($MN)
  • Table 9 Global Immunohistochemistry (IHC) Market Outlook, By Blocking Sera and Reagents (2021-2030) ($MN)
  • Table 10 Global Immunohistochemistry (IHC) Market Outlook, By Fixation Reagents (2021-2030) ($MN)
  • Table 11 Global Immunohistochemistry (IHC) Market Outlook, By Histological Stains (2021-2030) ($MN)
  • Table 12 Global Immunohistochemistry (IHC) Market Outlook, By Chromogenic Substrates (2021-2030) ($MN)
  • Table 13 Global Immunohistochemistry (IHC) Market Outlook, By Organic Solvents (2021-2030) ($MN)
  • Table 14 Global Immunohistochemistry (IHC) Market Outlook, By Stabilizers (2021-2030) ($MN)
  • Table 15 Global Immunohistochemistry (IHC) Market Outlook, By Mounting Solutions (2021-2030) ($MN)
  • Table 16 Global Immunohistochemistry (IHC) Market Outlook, By Antigen Retrieval Solutions (2021-2030) ($MN)
  • Table 17 Global Immunohistochemistry (IHC) Market Outlook, By Other Reagents (2021-2030) ($MN)
  • Table 18 Global Immunohistochemistry (IHC) Market Outlook, By Kits (2021-2030) ($MN)
  • Table 19 Global Immunohistochemistry (IHC) Market Outlook, By IHC Kits for Animal tissue (2021-2030) ($MN)
  • Table 20 Global Immunohistochemistry (IHC) Market Outlook, By IHC Kits for Human tissue (2021-2030) ($MN)
  • Table 21 Global Immunohistochemistry (IHC) Market Outlook, By Equipment (2021-2030) ($MN)
  • Table 22 Global Immunohistochemistry (IHC) Market Outlook, By Slide Scanners (2021-2030) ($MN)
  • Table 23 Global Immunohistochemistry (IHC) Market Outlook, By Automated Cover Slippers (2021-2030) ($MN)
  • Table 24 Global Immunohistochemistry (IHC) Market Outlook, By Microtomes (2021-2030) ($MN)
  • Table 25 Global Immunohistochemistry (IHC) Market Outlook, By Visualization Equipment (2021-2030) ($MN)
  • Table 26 Global Immunohistochemistry (IHC) Market Outlook, By Slide Labelers (2021-2030) ($MN)
  • Table 27 Global Immunohistochemistry (IHC) Market Outlook, By Tissue Microarrays (2021-2030) ($MN)
  • Table 28 Global Immunohistochemistry (IHC) Market Outlook, By Paraffin Dispensers (2021-2030) ($MN)
  • Table 29 Global Immunohistochemistry (IHC) Market Outlook, By Slide-staining Systems (2021-2030) ($MN)
  • Table 30 Global Immunohistochemistry (IHC) Market Outlook, By Tissue Processing Systems (2021-2030) ($MN)
  • Table 31 Global Immunohistochemistry (IHC) Market Outlook, By Other Equipment (2021-2030) ($MN)
  • Table 32 Global Immunohistochemistry (IHC) Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 Global Immunohistochemistry (IHC) Market Outlook, By Application (2021-2030) ($MN)
  • Table 34 Global Immunohistochemistry (IHC) Market Outlook, By Diagnostic Application (2021-2030) ($MN)
  • Table 35 Global Immunohistochemistry (IHC) Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 36 Global Immunohistochemistry (IHC) Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 37 Global Immunohistochemistry (IHC) Market Outlook, By Autoimmune diseases (2021-2030) ($MN)
  • Table 38 Global Immunohistochemistry (IHC) Market Outlook, By Nephrological diseases (2021-2030) ($MN)
  • Table 39 Global Immunohistochemistry (IHC) Market Outlook, By Neurological diseases (2021-2030) ($MN)
  • Table 40 Global Immunohistochemistry (IHC) Market Outlook, By Ophthalmic (2021-2030) ($MN)
  • Table 41 Global Immunohistochemistry (IHC) Market Outlook, By Dental Diseases (2021-2030) ($MN)
  • Table 42 Global Immunohistochemistry (IHC) Market Outlook, By Cardiovascular (2021-2030) ($MN)
  • Table 43 Global Immunohistochemistry (IHC) Market Outlook, By Dermatological (2021-2030) ($MN)
  • Table 44 Global Immunohistochemistry (IHC) Market Outlook, By Other Diagnostic Applications (2021-2030) ($MN)
  • Table 45 Global Immunohistochemistry (IHC) Market Outlook, By Research application (2021-2030) ($MN)
  • Table 46 Global Immunohistochemistry (IHC) Market Outlook, By Drug development and Testing (2021-2030) ($MN)
  • Table 47 Global Immunohistochemistry (IHC) Market Outlook, By Developmental Biology (2021-2030) ($MN)
  • Table 48 Global Immunohistochemistry (IHC) Market Outlook, By Stem Cell Research (2021-2030) ($MN)
  • Table 49 Global Immunohistochemistry (IHC) Market Outlook, By Forensic applications (2021-2030) ($MN)
  • Table 50 Global Immunohistochemistry (IHC) Market Outlook, By Other Research Applications (2021-2030) ($MN)
  • Table 51 Global Immunohistochemistry (IHC) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 52 Global Immunohistochemistry (IHC) Market Outlook, By End user (2021-2030) ($MN)
  • Table 53 Global Immunohistochemistry (IHC) Market Outlook, By Forensic Laboratories (2021-2030) ($MN)
  • Table 54 Global Immunohistochemistry (IHC) Market Outlook, By Biopharma Companies (2021-2030) ($MN)
  • Table 55 Global Immunohistochemistry (IHC) Market Outlook, By Hospitals & Diagnostic Laboratories (2021-2030) ($MN)
  • Table 56 Global Immunohistochemistry (IHC) Market Outlook, By Academic & research Institutes (2021-2030) ($MN)
  • Table 57 Global Immunohistochemistry (IHC) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.